Once-daily QVA149 has a good safety profile in patients with COPD
T. Welte, C. Vogelmeier, R. Dahl, K. R. Chapman, M. Rudolf, R. Mehta, P. D'Andrea, H. Chen, D. Banerji (Hanover, Marburg, Germany; Aarhus, Denmark; Toronto, Canada; Middlesex, United Kingdom; Indore, India; East Hanover, United States Of America)
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Welte, C. Vogelmeier, R. Dahl, K. R. Chapman, M. Rudolf, R. Mehta, P. D'Andrea, H. Chen, D. Banerji (Hanover, Marburg, Germany; Aarhus, Denmark; Toronto, Canada; Middlesex, United Kingdom; Indore, India; East Hanover, United States Of America). Once-daily QVA149 has a good safety profile in patients with COPD. Eur Respir J 2013; 42: Suppl. 57, 757
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: